Lam Research Corporation vs UiPath Inc — how do they compare? Lam Research Corporation trades at $319.95 (market cap $401.19B), while UiPath Inc trades at $13.5 (market cap $6.91B). The key difference: Lam Research Corporation is far larger — about 58.1× UiPath Inc's market cap, and Lam Research Corporation pays a 0.41% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and UiPath Inc for 139 Days on average.
| LRCX | PATH | |
|---|---|---|
Market Cap | $401.19B | $6.91B |
Volume | 8,960,892 | 34,321,250 |
Sector | Technology | Technology |
52-Week High | $433.33 | $19.29 |
52-Week Low | $131.37 | $9.38 |
Typical Hold Time | 60 Days | 139 Days |
Enterprise Value | $399.35B | $5.70B |
Dividend Yield | 0.41% | — |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) is trading at $319.42, down 3.06% on the day, amid a broader bearish technical signal. The stock exhibits strong fundamentals with revenue of $18.44B in 2025 and a net income margin of 31.27%, supported by three consecutive quarterly earnings beats. Analyst consensus is overwhelmingly bullish with a 78% buy rating and a $375.68 price target, citing AI-driven demand for semiconductor equipment. Recent news highlights the company's strategic positioning in AI infrastructure and margin expansion targets.
The outlook for LRCX is positive, driven by robust earnings growth and expanding profitability, though valuation multiples remain elevated. Key risks include cyclical semiconductor demand and competitive pressures. With strong institutional support and a clear growth trajectory, the stock presents a compelling opportunity for long-term investors, contingent on sustained execution in a dynamic market.
UiPath (PATH) trades at $13.45, up 2.87% today, showing technical bullish momentum despite mixed earnings. The company demonstrates strong revenue growth from $1.43B in 2025 to projected $1.7B in 2026, with net income turning positive at $362M. Recent partnerships with Snowflake and BDO highlight strategic expansion in AI orchestration, while analyst consensus remains cautious with 67% hold ratings.
PATH offers growth potential through AI automation leadership but faces execution risks amid competitive pressures. The stock trades below consensus target of $15.13, suggesting 12% upside if guidance is met. Key risks include pricing pressure and integration challenges with new partnerships.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →